Ocular Therapeutix, Inc. (FRA:0OT)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.56B +51.4% |
| Revenue (ttm) | 45.13M -12.8% |
| Net Income | -251.95M |
| EPS | -1.26 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 7.05 |
| Previous Close | 7.10 |
| Day's Range | 6.90 - 7.05 |
| 52-Week Range | 5.68 - 13.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ... [Read more]
Financial Performance
In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.
Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum
SOL-1 met all FDA evidentiary standards, showing strong efficacy, durability, and safety, with immediate physician adoption expected. Approval is anticipated based on SOL-1 alone, while SOL-R and SOL-X support broader safety, commercial, and long-term outcome goals.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experien...
Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026
The pivotal SOL-1 study showed unprecedented disease control and durability, supporting plans to file for approval based on a single study. Broad adoption is expected due to strong clinical results, ease of integration, and significant market opportunity in both wet AMD and diabetic retinopathy.
Ocular Therapeutix Earnings Call Transcript: Q1 2026
AXPAXLI achieved unprecedented superiority and durability in wet AMD, with strong safety and high patient retention, supporting an NDA submission and accelerated commercial plans. Cash reserves of $667 million provide runway into 2028 as multiple pivotal trials progress.
Ocular Therapeutix Earnings release: Q1 2026
Ocular Therapeutix released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Ocular Therapeutix Quarterly report: Q1 2026
Ocular Therapeutix has published its Q1 2026 quarterly earnings report on May 5, 2026.
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
Reports Q1 revenue $10.79M, consensus $12.7M. “2026 is off to a tremendous start for Ocular, driven by the superiority demonstrated with AXPAXLI in the landmark SOL-1 Phase 3 trial in…
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever suc...
Ocular Therapeutix Proxy statement: Proxy filing
Ocular Therapeutix filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Ocular Therapeutix Proxy statement: Proxy filing
Ocular Therapeutix filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Ocular Therapeutix enrolls first patient in Axpali trial
Ocular Therapeutix (OCUL) announced that the first patient has been enrolled in the SOL-X long-term extension trial for Axpali for the treatment of wet age-related macular degeneration. Published firs...
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in eithe...
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Transcript: HCW @ Home
AXPAXLI's phase III SOL-1 trial met robust superiority and safety endpoints, supporting a single pivotal trial approval pathway for wet AMD. The drug's unique profile and commercial readiness position it for broad adoption and premium pricing, with ongoing trials and a strong IP portfolio supporting long-term growth.
Ocular Therapeutix reports additional Axpaxli trial data
Ocular Therapeutix (OCUL) announced additional positive Week 52 data from the SOL-1 Phase 3 superiority trial of Axpaxli its investigational product candidate for the treatment of wet age-related macu...
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference
AXPAXLI's phase III SOL-1 trial demonstrated robust superiority over anti-VEGF, earning strong medical and strategic interest. Safety concerns about floaters were addressed with data, and regulatory confidence is high for FDA approval based on SOL-1 alone, with SOLAR expected to further support commercial adoption.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026
AXPAXLI achieved the first-ever phase III superiority result over anti-VEGF therapy in wet AMD, with robust disease control and a strong safety profile. Regulatory submission is underway, supported by a single pivotal trial and a solid financial position, with further updates expected as the SOLAR study progresses.
Ocular Therapeutix price target raised to $27 from $24 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Ocular Therapeutix (OCUL) to $27 from $24 and keeps a Buy rating on the shares. Comprehensive analyses from the Phase…
Ocular Therapeutix price target raised to $28 from $21 at Clear Street
Clear Street raised the firm’s price target on Ocular Therapeutix (OCUL) to $28 from $21 and keeps a Buy rating on the shares after the company presented detailed data from…
Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference
A first-ever superiority study in retina met its primary endpoint with robust data consistency and unprecedented disease control. The drug is expected to secure a unique superiority label, supporting premium pricing and broad indications, with no major safety concerns and strong real-world potential.
Ocular Therapeutix Transcript: Study update
AXPAXLI (OTX-TKI) demonstrated superior, durable vision maintenance and anatomic control over aflibercept in the phase III SOL-1 trial, with a strong safety profile and high rescue-free rates up to 12 months. Regulatory submission is planned based on SOL-1 alone, with broad clinical adoption anticipated.